The present invention pertains to medical devices, and methods for manufacturing medical devices. More particularly, the present invention pertains to catheters that can vary in stiffness
A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include guidewires, catheters, and the like. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices as well as alternative methods for manufacturing and using medical devices.
The invention provides design, material, manufacturing method, and use alternatives for medical devices. An example medical device may include an elongate inner member having a guidewire lumen extending therethrough. An outer member may be disposed about the inner member. An inflation lumen may be formed between the inner member and the outer member. The medical device may be configured to have a first stiffness when the inflation lumen is free of inflation media and a second stiffness different from the first stiffness when inflation media is disposed within the inflation lumen. In addition, the inner member may include a collapsible region that is configured to deflect radially inward when inflation media is disposed within the inflation lumen.
An example method for navigating a medical device through the vasculature may include providing a catheter. The catheter may include an elongate inner member having a guidewire lumen extending therethrough, an outer member disposed about the inner member, and an inflation lumen, which may be defined between the inner member and the outer member. The method may also include advancing a guidewire through the vasculature to a position adjacent to an area of interest, advancing the catheter over the guidewire, and infusing inflation media into the inflation lumen. Infusing inflation media into the inflation lumen may increase the stiffness of the catheter and it may deflect a portion of the inner member radially inward such that the inner member engages the guidewire.
An example variable stiffness catheter may include a catheter shaft. The catheter shaft may include an inner shaft and an outer shaft. A lumen may be formed between the inner shaft and the outer shaft. Infusion of a media into the lumen may increase the stiffness of the catheter shaft. Additionally, the inner shaft may have a collapsible region that is configured to deflect radially inward when media is infused into the lumen.
The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present invention. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.
The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:
While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
In the illustrated embodiment, inner shaft 18 is shown as having a length that is substantially the same as outer shaft 22. In other words, inner shaft 18 may extend along substantially the entire length of catheter shaft 12. Accordingly, guidewire lumen 20 may also extend along substantially the entire length of catheter 12 such that catheter 10 is an “over-the-wire” catheter. This, however, is not intended to be limiting as other catheters are contemplated where catheter 10 is a “single-operator-exchange” or “rapid-exchange” catheter, as these terms would be understood by one skilled in the art. In these embodiments, inner shaft 18 may extend along only a distal portion of outer shaft 22 and a port or opening (not shown) may be formed in the wall of outer shaft 22 that provides access to guidewire lumen 20.
Inner shaft 18 and outer shaft 22 may have a number of different configurations and/or material compositions. For example, inner shaft 18, outer shaft 22, or both may include one or more layers of material. In one example, inner shaft 18 may include three layers of material including an inner layer, and outer layer, and a tie layer disposed therebetween. In addition, inner shaft 18, outer shaft 22, or both may include a reinforcing structure such as a braid, mesh, coil, or other structure (not shown). This may provide catheter shaft 12 with improved strength.
One or more marker members or bands 23 may be disposed on inner shaft 18. Marker bands 23 may allow a clinician to more easily visualize catheter 10 under fluoroscopy or other visualization techniques (e.g., MRI, etc.). Because marker bands 23 are disposed on inner shaft 18 and because outer shaft 22 is also disposed about inner shaft 18, marker bands 23 may be covered or “encapsulated” within catheter shaft 12. Accordingly, marker bands 23 may be not exposed along the exterior of catheter shaft 12 where they might otherwise be susceptible to snagging or catching along the vasculature.
When using catheters (e.g., catheter 10) to gain access to lesions within the vasculature, it may be useful for the catheters to be highly flexible. This is because, for example, the vasculature may include a number of relatively sharp bends or take-offs. When navigating and/or treating the anatomy, it is possible that the catheter may encounter a lesion such as what is known as a chronic total occlusion. Such occlusion, which may be calcified or otherwise hardened, may be difficult to navigate through and/or treat, particularly with a highly flexible catheter.
Catheter 10 may be designed so as to have desirable flexibility characteristics so that it may be efficiently navigated through the anatomy (e.g., its flexibility may be comparable to that of catheters that are typically used to gain access to a variety of points within the vasculature). In addition, in order to more efficiently cross lesions such as a chronic total occlusions, catheter 10 may also have a variable flexibility or stiffness. Because of this, it may be possible for the clinician to alter the stiffness of catheter 10 (e.g., may provide “on demand” variability in stiffness) during a vascular intervention so that the flexibility and/or stiffness characteristics of catheter 10 can be tailored to the needs of the intervention. For example, catheter 10 may be configured to be relatively flexible so that it can efficiently navigate sharp bends or turns in the anatomy. In addition, catheter 10 may also be configured so that a clinician can increase the stiffness thereof, which may allow catheter 10 to be used to and/or aid in more efficiently crossing an occlusion such as a chronic total occlusion.
In at least some embodiments, catheter 10 may be configured to have a varying stiffness through the infusion of media 26 for example inflation media, into lumen 24 as shown in
It can be appreciated that in order to contain media 26, inner shaft 18 and outer shaft 22 may be attached, for example at their distal ends, and form a closed tip. The exact configuration of the tip can vary. For example, some embodiments may include a relatively gentle taper so as to provide catheter 10 with an atraumatic tip. Some of this and other embodiments may include an elongated tip or low profile tip, which may allow catheter 10 to probe deeper within the anatomy and within relatively narrow locations including the neurological vasculature.
In addition to having a variable stiffness, inner member 18 may also be configured to deflect radially inward or otherwise collapse as shown in
While
Ultimately, it may be decided that additional pushability and/or stiffness may be necessary in order to cross occlusion 32. Accordingly, inflation media 26 may be infused into lumen 24 as shown in
Outer shaft 122 may include a deflectable portion 134. In this example, deflectable portion 134 is configured to deflect radially outward. In at least some embodiments, portion 134 may resemble a balloon or inflatable structure that deflects radially outward when inflation media 126 is infused into catheter 110. Deflection portion 134 may extend along only a discrete portion of outer shaft 122 (e.g., along a distal region), along multiple discrete portions of outer shaft 122, or along substantially the entire length of outer shaft 122. Deflectable portion 134 may be desirable for a number of reasons. For example, portion 134 may be used to expand or otherwise break up an occlusion (e.g., like occlusion 32) so that catheter 110 can be advanced through the occlusion. For example, catheter 110 may be advanced partially through or into an occlusion and deflectable portion 134 may be enlarged (e.g., deflected radially outward) to help break up the occlusion.
The materials that can be used for the various components of catheter 10 (and/or other catheters disclosed herein) and the various catheter shafts disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion makes reference to catheter shaft 12 and other components of catheter 10. However, this is not intended to limit the devices and methods described herein, as the discussion may be applied to other similar tubular members and/or components of tubular members or devices disclosed herein.
Catheter shaft 12 and/or other components of catheter 10 may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material. Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.
As alluded to herein, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear that the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.
In some cases, linear elastic and/or non-super-elastic nitinol may also be distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also can be distinguished based on its composition), which may accept only about 0.2 to 0.44 percent strain before plastically deforming.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by differential scanning calorimetry (DSC) and dynamic metal thermal analysis (DMTA) analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60 degrees Celsius (°C.) to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Some examples of nickel titanium alloys are disclosed in U.S. Pat. Nos. 5,238,004 and 6,508,803, which are incorporated herein by reference. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.
In at least some embodiments, portions or all of catheter shaft 12 may also be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of catheter 10 in determining its location. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of catheter 10 to achieve the same result.
In some embodiments, a degree of Magnetic Resonance Imaging (MRI) compatibility is imparted into catheter 10. For example, catheter shaft 12, or portions thereof, may be made of a material that does not substantially distort the image and create substantial artifacts (i.e., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. Catheter shaft 12, or portions thereof, may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.
A sheath or covering (not shown) may be disposed over portions or all of catheter shaft 12 that may define a generally smooth outer surface for catheter 10. In other embodiments, however, such a sheath or covering may be absent from a portion of all of catheter 10, such that catheter shaft 12 may form the outer surface. The sheath may be made from a polymer or other suitable material. Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.
In some embodiments, the exterior surface of the catheter 10 (including, for example, the exterior surface of catheter shaft 12) may be sandblasted, beadblasted, sodium bicarbonate-blasted, electropolished, etc. In these as well as in some other embodiments, a coating, for example a lubricious, a hydrophilic, a protective, or other type of coating may be applied over portions or all of the sheath, or in embodiments without a sheath over portion of catheter shaft 12, or other portions of catheter 10. Alternatively, the sheath may comprise a lubricious, hydrophilic, protective, or other type of coating. Hydrophobic coatings such as fluoropolymers provide a dry lubricity which improves guidewire handling and device exchanges. Lubricious coatings improve steerability and improve lesion crossing capability. Suitable lubricious polymers are well known in the art and may include silicone and the like, hydrophilic polymers such as high-density polyethylene (HDPE), polytetrafluoroethylene (PTFE), polyarylene oxides, polyvinylpyrolidones, polyvinylalcohols, hydroxy alkyl cellulosics, algins, saccharides, caprolactones, and the like, and mixtures and combinations thereof. Hydrophilic polymers may be blended among themselves or with formulated amounts of water insoluble compounds (including some polymers) to yield coatings with suitable lubricity, bonding, and solubility. Some other examples of such coatings and materials and methods used to create such coatings can be found in U.S. Pat. Nos. 6,139,510 and 5,772,609, which are incorporated herein by reference.
The coating and/or sheath may be formed, for example, by coating, extrusion, co-extrusion, interrupted layer co-extrusion (ILC), or fusing several segments end-to-end. The layer may have a uniform stiffness or a gradual reduction in stiffness from the proximal end to the distal end thereof. The gradual reduction in stiffness may be continuous as by ILC or may be stepped as by fusing together separate extruded tubular segments. The outer layer may be impregnated with a radiopaque filler material to facilitate radiographic visualization. Those skilled in the art will recognize that these materials can vary widely without deviating from the scope of the present invention.
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
This application claims the benefit of U.S. Provisional Application Ser. No. 61/449,271, filed Mar. 4, 2011, the entire disclosure of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3472230 | Fogarty | Oct 1969 | A |
3592186 | Oster | Jul 1971 | A |
3683904 | Forster | Aug 1972 | A |
3889657 | Baumgarten | Jun 1975 | A |
3952747 | Kimmell, Jr. | Apr 1976 | A |
3996938 | Clark, III | Dec 1976 | A |
4046150 | Schwartz et al. | Sep 1977 | A |
4425908 | Simon | Jan 1984 | A |
4447227 | Kotsanis | May 1984 | A |
4580568 | Gianturco | Apr 1986 | A |
4590938 | Segura et al. | May 1986 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4631052 | Kensey | Dec 1986 | A |
4643184 | Mobin-Uddin | Feb 1987 | A |
4650466 | Luther | Mar 1987 | A |
4662885 | DiPisa, Jr. | May 1987 | A |
4705517 | DiPisa, Jr. | Nov 1987 | A |
4706671 | Weinrib | Nov 1987 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4728319 | Masch | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4790812 | Hawkins, Jr. et al. | Dec 1988 | A |
4790813 | Kensey | Dec 1988 | A |
4794928 | Kletschka | Jan 1989 | A |
4794931 | Yock | Jan 1989 | A |
4800882 | Gianturco | Jan 1989 | A |
4807626 | McGirr | Feb 1989 | A |
4842579 | Shiber | Jun 1989 | A |
4857045 | Rydell | Aug 1989 | A |
4857046 | Stevens et al. | Aug 1989 | A |
4867157 | McGurk-Burleson et al. | Sep 1989 | A |
4873978 | Ginsburg | Oct 1989 | A |
4898575 | Fischell et al. | Feb 1990 | A |
4907336 | Gianturco | Mar 1990 | A |
4921478 | Solano et al. | May 1990 | A |
4921484 | Hillstead | May 1990 | A |
4926858 | Gifford, III et al. | May 1990 | A |
4932959 | Horzewski et al. | Jun 1990 | A |
4950277 | Farr | Aug 1990 | A |
4955895 | Sugiyama et al. | Sep 1990 | A |
4957482 | Shiber | Sep 1990 | A |
4969891 | Gewertz | Nov 1990 | A |
4979951 | Simpson | Dec 1990 | A |
4986807 | Farr | Jan 1991 | A |
4998539 | Delsanti | Mar 1991 | A |
5002560 | Machold et al. | Mar 1991 | A |
RE33569 | Gifford, III et al. | Apr 1991 | E |
5007896 | Shiber | Apr 1991 | A |
5007917 | Evans | Apr 1991 | A |
5011488 | Ginsburg | Apr 1991 | A |
5019088 | Farr | May 1991 | A |
5041126 | Gianturco | Aug 1991 | A |
5053008 | Bajaj | Oct 1991 | A |
5053044 | Mueller et al. | Oct 1991 | A |
5071407 | Termin et al. | Dec 1991 | A |
5071425 | Gifford, III et al. | Dec 1991 | A |
5085662 | Willard | Feb 1992 | A |
5087265 | Summers | Feb 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5100424 | Jang et al. | Mar 1992 | A |
5100425 | Fischell et al. | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5104399 | Lazarus | Apr 1992 | A |
5106376 | Mononen et al. | Apr 1992 | A |
5108419 | Reger et al. | Apr 1992 | A |
5116305 | Milder et al. | May 1992 | A |
5133733 | Rasmussen et al. | Jul 1992 | A |
5135531 | Shiber | Aug 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5152777 | Goldberg et al. | Oct 1992 | A |
5160342 | Reger et al. | Nov 1992 | A |
5171233 | Amplatz et al. | Dec 1992 | A |
5190546 | Jervis | Mar 1993 | A |
5195955 | Don Michael | Mar 1993 | A |
5217434 | Arney | Jun 1993 | A |
5224953 | Morgentaler | Jul 1993 | A |
5231989 | Middleman et al. | Aug 1993 | A |
5238004 | Sahatjian et al. | Aug 1993 | A |
5306286 | Stack et al. | Apr 1994 | A |
5314444 | Gianturco | May 1994 | A |
5314472 | Fontaine | May 1994 | A |
5318576 | Plassche, Jr. et al. | Jun 1994 | A |
5324259 | Taylor et al. | Jun 1994 | A |
5329942 | Gunther et al. | Jul 1994 | A |
5330484 | Gunther et al. | Jul 1994 | A |
5330500 | Song | Jul 1994 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5354310 | Garnic et al. | Oct 1994 | A |
5356423 | Tihon et al. | Oct 1994 | A |
5366464 | Belknap | Nov 1994 | A |
5366473 | Winston et al. | Nov 1994 | A |
5370657 | Irie | Dec 1994 | A |
5370683 | Fontaine | Dec 1994 | A |
5376100 | Lefebvre | Dec 1994 | A |
5383887 | Nadal | Jan 1995 | A |
5383892 | Cardon et al. | Jan 1995 | A |
5383926 | Lock et al. | Jan 1995 | A |
5387235 | Chuter | Feb 1995 | A |
5395349 | Quiachon et al. | Mar 1995 | A |
5397345 | Lazerus | Mar 1995 | A |
5405377 | Cragg | Apr 1995 | A |
5409454 | Fischell et al. | Apr 1995 | A |
5415630 | Gory et al. | May 1995 | A |
5419774 | Willard et al. | May 1995 | A |
5421832 | Lefebvre | Jun 1995 | A |
5423742 | Theron | Jun 1995 | A |
5423885 | Williams | Jun 1995 | A |
5425765 | Tiefenbrun et al. | Jun 1995 | A |
5443498 | Fontaine | Aug 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5456667 | Ham et al. | Oct 1995 | A |
5462529 | Simpson et al. | Oct 1995 | A |
5476104 | Sheahon | Dec 1995 | A |
5484418 | Quiachon et al. | Jan 1996 | A |
5499973 | Saab | Mar 1996 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5512044 | Duer | Apr 1996 | A |
5527354 | Fontaine et al. | Jun 1996 | A |
5531689 | Burns et al. | Jul 1996 | A |
5536242 | Willard et al. | Jul 1996 | A |
5540707 | Ressemann et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5562724 | Vorwerk et al. | Oct 1996 | A |
5569274 | Rapacki et al. | Oct 1996 | A |
5569275 | Kotula et al. | Oct 1996 | A |
5634897 | Dance et al. | Jun 1997 | A |
5658296 | Bates et al. | Aug 1997 | A |
5662671 | Barbut et al. | Sep 1997 | A |
5669933 | Simon et al. | Sep 1997 | A |
5695519 | Summers et al. | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5720764 | Naderlinger | Feb 1998 | A |
5728066 | Daneshvar | Mar 1998 | A |
5730734 | Adams et al. | Mar 1998 | A |
5746758 | Nordgren et al. | May 1998 | A |
5749848 | Jang et al. | May 1998 | A |
5749849 | Engelson | May 1998 | A |
5769816 | Barbut et al. | Jun 1998 | A |
5772609 | Nguyen et al. | Jun 1998 | A |
5779716 | Cano et al. | Jul 1998 | A |
5792300 | Inderbitzen et al. | Aug 1998 | A |
5795322 | Boudewijn | Aug 1998 | A |
5797952 | Klein | Aug 1998 | A |
5800457 | Gelbfish | Sep 1998 | A |
5800525 | Bachinski et al. | Sep 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Daniel et al. | Sep 1998 | A |
5817102 | Johnson et al. | Oct 1998 | A |
5827324 | Cassell et al. | Oct 1998 | A |
5833604 | Houser et al. | Nov 1998 | A |
5833644 | Zadno-Azizi et al. | Nov 1998 | A |
5833650 | Imran | Nov 1998 | A |
5846260 | Maahs | Dec 1998 | A |
5848964 | Samuels | Dec 1998 | A |
5876367 | Kaganov et al. | Mar 1999 | A |
5879324 | von Hoffmann | Mar 1999 | A |
5891112 | Samson | Apr 1999 | A |
5893867 | Bagaoisan et al. | Apr 1999 | A |
5895399 | Barbut et al. | Apr 1999 | A |
5897536 | Nap et al. | Apr 1999 | A |
5902263 | Patterson et al. | May 1999 | A |
5906618 | Larson, III | May 1999 | A |
5908395 | Stalker et al. | Jun 1999 | A |
5908435 | Samuels | Jun 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5916193 | Stevens et al. | Jun 1999 | A |
5919162 | Burns | Jul 1999 | A |
5925016 | Chornenky et al. | Jul 1999 | A |
5925060 | Forber | Jul 1999 | A |
5925062 | Purdy | Jul 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5928203 | Davey et al. | Jul 1999 | A |
5928218 | Gelbfish | Jul 1999 | A |
5934284 | Plaia et al. | Aug 1999 | A |
5935139 | Bates | Aug 1999 | A |
5938645 | Gordon | Aug 1999 | A |
5941869 | Patterson et al. | Aug 1999 | A |
5941896 | Kerr | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5951585 | Cathcart et al. | Sep 1999 | A |
5954745 | Gertler et al. | Sep 1999 | A |
5976172 | Homsma et al. | Nov 1999 | A |
5989210 | Morris et al. | Nov 1999 | A |
5989271 | Bonnette et al. | Nov 1999 | A |
5989281 | Barbut et al. | Nov 1999 | A |
5993469 | Mckenzie et al. | Nov 1999 | A |
5997557 | Barbut et al. | Dec 1999 | A |
6001118 | Daniel et al. | Dec 1999 | A |
6007557 | Ambrisco et al. | Dec 1999 | A |
6010522 | Barbut et al. | Jan 2000 | A |
6013085 | Howard | Jan 2000 | A |
6027520 | Tsugita et al. | Feb 2000 | A |
6051014 | Jang | Apr 2000 | A |
6053932 | Daniel et al. | Apr 2000 | A |
6059814 | Ladd | May 2000 | A |
6068645 | Tu | May 2000 | A |
6086605 | Barbut et al. | Jul 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6139510 | Palermo | Oct 2000 | A |
6142987 | Tsugita | Nov 2000 | A |
6152946 | Broome et al. | Nov 2000 | A |
6165200 | Tsugita et al. | Dec 2000 | A |
6168579 | Tsugita | Jan 2001 | B1 |
6171327 | Daniel et al. | Jan 2001 | B1 |
6179851 | Barbut et al. | Jan 2001 | B1 |
6179859 | Bates et al. | Jan 2001 | B1 |
6179861 | Khosravi et al. | Jan 2001 | B1 |
6203561 | Ramee et al. | Mar 2001 | B1 |
6214026 | Lepak et al. | Apr 2001 | B1 |
6231543 | Hegde et al. | May 2001 | B1 |
6231545 | Kriesel et al. | May 2001 | B1 |
6368338 | Konya et al. | Apr 2002 | B1 |
6398798 | Selmon et al. | Jun 2002 | B2 |
6428552 | Sparks | Aug 2002 | B1 |
6500166 | Zadno Azizi et al. | Dec 2002 | B1 |
6506178 | Schubart et al. | Jan 2003 | B1 |
6508803 | Horikawa et al. | Jan 2003 | B1 |
6508825 | Selmon et al. | Jan 2003 | B1 |
6511458 | Milo et al. | Jan 2003 | B2 |
6514217 | Selmon et al. | Feb 2003 | B1 |
6533751 | Cragg et al. | Mar 2003 | B2 |
6533753 | Haarstad et al. | Mar 2003 | B1 |
6544276 | Azizi | Apr 2003 | B1 |
6547768 | Trotta | Apr 2003 | B2 |
6579302 | Duerig et al. | Jun 2003 | B2 |
6605062 | Hurley et al. | Aug 2003 | B1 |
6786886 | Miller et al. | Sep 2004 | B2 |
6837867 | Kortelling | Jan 2005 | B2 |
7695465 | Tomaschko et al. | Apr 2010 | B2 |
8292827 | Musbach et al. | Oct 2012 | B2 |
20080015541 | Rosenbluth et al. | Jan 2008 | A1 |
20100125244 | Mcandrew | May 2010 | A1 |
20100168007 | Cruise et al. | Jul 2010 | A1 |
Number | Date | Country |
---|---|---|
2821048 | Jul 1980 | DE |
3417738 | Nov 1985 | DE |
4030998 | Apr 1998 | DE |
0200688 | Nov 1986 | EP |
0293605 | Dec 1988 | EP |
0411118 | Feb 1991 | EP |
0427429 | May 1991 | EP |
0437121 | Jul 1991 | EP |
0472334 | Feb 1992 | EP |
0472368 | Feb 1992 | EP |
0517075 | Dec 1992 | EP |
0533511 | Mar 1993 | EP |
0655228 | May 1995 | EP |
0686379 | Dec 1995 | EP |
0696447 | Feb 1996 | EP |
0737450 | Oct 1996 | EP |
0743046 | Nov 1996 | EP |
0759287 | Feb 1997 | EP |
0771549 | May 1997 | EP |
0784988 | Jul 1997 | EP |
0852132 | Jul 1998 | EP |
0934729 | Aug 1999 | EP |
2580504 | Oct 1986 | FR |
2643250 | Aug 1990 | FR |
2666980 | Mar 1992 | FR |
2768326 | Mar 1999 | FR |
2020557 | Jan 1983 | GB |
2044109 | Aug 1983 | GB |
8187294 | Jul 1996 | JP |
764684 | Sep 1980 | SU |
WO 9203097 | Mar 1992 | WO |
WO 9414389 | Jul 1994 | WO |
WO 9424946 | Nov 1994 | WO |
WO 9601591 | Jan 1996 | WO |
WO 9610375 | Apr 1996 | WO |
WO 9619941 | Jul 1996 | WO |
WO 9623441 | Aug 1996 | WO |
WO 9633677 | Oct 1996 | WO |
WO 9717100 | May 1997 | WO |
WO 9727808 | Aug 1997 | WO |
WO 9742879 | Nov 1997 | WO |
WO 9802084 | Jan 1998 | WO |
WO 9802112 | Jan 1998 | WO |
WO 9823322 | Jun 1998 | WO |
WO 9833443 | Aug 1998 | WO |
WO 9834673 | Aug 1998 | WO |
WO 9836786 | Aug 1998 | WO |
WO 9838920 | Sep 1998 | WO |
WO 9838929 | Sep 1998 | WO |
WO 9839046 | Sep 1998 | WO |
WO 9839053 | Sep 1998 | WO |
WO 9846297 | Oct 1998 | WO |
WO 9847447 | Oct 1998 | WO |
WO 9849952 | Nov 1998 | WO |
WO 9850103 | Nov 1998 | WO |
WO 9851237 | Nov 1998 | WO |
WO 9855175 | Dec 1998 | WO |
WO 9909895 | Mar 1999 | WO |
WO 9922673 | May 1999 | WO |
WO 9923976 | May 1999 | WO |
WO 9925252 | May 1999 | WO |
WO 9930766 | Jun 1999 | WO |
WO 9940964 | Aug 1999 | WO |
WO 9942059 | Aug 1999 | WO |
WO 9944510 | Sep 1999 | WO |
WO 9944542 | Sep 1999 | WO |
WO 9955236 | Nov 1999 | WO |
WO 9958068 | Nov 1999 | WO |
WO 0007655 | Feb 2000 | WO |
WO 0009054 | Feb 2000 | WO |
WO 0016705 | Mar 2000 | WO |
WO 0049970 | Aug 2000 | WO |
Entry |
---|
“Atherosclerotic Disease of the Aortic Arch as a Risk Factor of Recurrent Ischemic Stroke”, The New England Journal of Medicine, 334(18):1216-1221, May 1996. |
“Endovascular Grafts, Stents Drive Interventional Radiology Growth”, Cardiovascular Device Update, 2(3):1-12, Mar. 1996. |
Cragg et al., “A New Percutaneous Vena Cava Filger,” AJR, 141:601-604, Sep. 1983. |
Cragg et al., “Nonsurgical Placement of Arterial Endoprosthesis: A New Technique Using Nitinol Wire”, AJR, 147(1):261-263, Apr. 1983. |
Diethrich et al., “Percutaneous Techniques for Endoluminal Carotid Interventions”, J. Endovasc. Surg., 3:182-202, 1996. |
Fadali, “A Filtering Device for the Prevention of Particulate Embolization During the Course of Cardiac Surgery”, Surgery, 64(3):634-639, Sep. 1968. |
Haissaguerre et al., “Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins”, The New England Journal of Medicine, 339(10):659-666, Sep. 1988. |
Jordan, Jr. et al., “Microemboli Detected by Transcranial Doppler Monitoring . . . ”, Cardiovascular Surgery, 7(1)33-38, Jan. 1999. |
Karalis et al., “Recognition and Embolic Potential of Intraaortic Atherosclerotic Debris”, American College of Cardiology, 17(1):73-78, Jan. 1991. |
Lesh, “Can Catheter Ablation Cure Atrial Fibrillation?”, ACC Current Journal Review, p. 38-40, Sep./Oct. 1997. |
Lund et al., “Long-Term Patentcy of Ductus Arteriosus After Balloon Dilation: An Experimental Study”, Laboratory Investigation, 69(4):772-774, Apr. 1984. |
Marache et al., “Percutaneous Transluminal Venous Angioplasty . . . ”, American Heart Journal, 125(2 pt. 1):362-366, Feb. 1993. |
Mazur et al., “Directional Atherectomy with the Omnicath™: A Unique New Catheter System”, Catheterization and Cardiovascular Diagnosis, 31:17-84, 1994. |
Moussa, MD, Issaam, “Stents Don't Require Systemic Anticoagulation . . . But the Technique (and results) Must be Optimal”, Journal of Invasive Cardiol., 8(E):3E-7E, 1996. |
Nakanishi et al., “Catheter Intervention to Venous System Using Expandable Metallic Stents”, Rinsho Kyobu Geka, 14(2): English Abstract Only, Apr. 1994. |
Onal et al., “Primary Stenting for Complex Atherosclerotic Plaques in Aortic and Iliac Stenoses”, Cardiovascular & Interventional Radiology, 21(5):386-392, 1998. |
Theron et al., “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection”, American Journal of Neuroradiology, 11:869-874, 1990. |
Tunick et al., “Protruding Atheromas in the Thoracic Aortic and Systematic Embolization”, 115(6):423-427, American College of Physicians, 1991. |
Tunick et al., “Protruding Atherosclerotic Plaque in the Aortic Archo F Patients with Systemic Embolization: A New Finding Seen by Transesophageal Echocardiography”, American Heart Journal, 120(3):658-660, Sep. 1990. |
Waksman et al., “Distal Embolization is Common After Directional Atherectomy . . . ,” American Heart Journal, 129(3):430-435, 1995. |
Wholey et al., PTA and Stents in the Treatment of Extracranial Circulation, The Journal of Invasive Cardiology, 8(E):25E-30E, 1996. |
Number | Date | Country | |
---|---|---|---|
20120253193 A1 | Oct 2012 | US |
Number | Date | Country | |
---|---|---|---|
61449271 | Mar 2011 | US |